Matti Kivikko

4.5k total citations · 1 hit paper
40 papers, 2.3k citations indexed

About

Matti Kivikko is a scholar working on Cardiology and Cardiovascular Medicine, Biomedical Engineering and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Matti Kivikko has authored 40 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Cardiology and Cardiovascular Medicine, 12 papers in Biomedical Engineering and 8 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Matti Kivikko's work include Heart Failure Treatment and Management (38 papers), Mechanical Circulatory Support Devices (12 papers) and Cardiovascular Function and Risk Factors (10 papers). Matti Kivikko is often cited by papers focused on Heart Failure Treatment and Management (38 papers), Mechanical Circulatory Support Devices (12 papers) and Cardiovascular Function and Risk Factors (10 papers). Matti Kivikko collaborates with scholars based in Finland, United Kingdom and Germany. Matti Kivikko's co-authors include Lasse Lehtonen, Markku S. Nieminen, Alexandre Mebazaa, Pentti Põder, Alain Cohen‐Solal, Franz X. Kleber, Robert J. Padley, Stuart Pocock, Milton Packer and Roopal Thakkar and has published in prestigious journals such as JAMA, Circulation and European Heart Journal.

In The Last Decade

Matti Kivikko

37 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Levosimendan vs Dobutamine for Patients With Acute Decompensated Heart Failure

2007 645 citations Alexandre Mebazaa, Markku S. Nieminen et al. profile →

Peers

Countries citing papers authored by Matti Kivikko

Since Specialization

Citations

This map shows the geographic impact of Matti Kivikko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matti Kivikko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matti Kivikko more than expected).

Fields of papers citing papers by Matti Kivikko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matti Kivikko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matti Kivikko. The network helps show where Matti Kivikko may publish in the future.

Co-authorship network of co-authors of Matti Kivikko

This figure shows the co-authorship network connecting the top 25 collaborators of Matti Kivikko. A scholar is included among the top collaborators of Matti Kivikko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matti Kivikko. Matti Kivikko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Levosimendan in Acute and Advanced Heart Failure: an Expert Perspective on Posology and Therapeutic Application 2018 ·Cardiovascular Drugs and Therapy ·Stefaan Bouchez, Francesco Fedele, George Giannakoulas, Finn Gustafsson, V.‐P. Harjola, Kristjan Karason, Matti Kivikko, Dirk von Lewinski, Fabrizio Oliva, Zoltán Papp, John Parissis, Piero Pollesello, Gerhard Pölzl, Carsten Tschöpe	44
2	Levosimendan meta-analyses: Is there a pattern in the effect on mortality? 2016 ·International Journal of Cardiology ·Piero Pollesello, John Parissis, Matti Kivikko, Veli‐Pekka Harjola	62
3	Effect of baseline characteristics on mortality in the SURVIVE trial on the effect of levosimendan vs dobutamine in acute heart failure: Sub-analysis of the Finnish patients 2016 ·International Journal of Cardiology ·Matti Kivikko, Piero Pollesello, Tuukka Tarvasmäki, Toni Sarapohja, Markku S. Nieminen, Veli‐Pekka Harjola	6
4	Oral Levosimendan Increases Cerebral Blood Flow Velocities in Patients with a History of Stroke or Transient Ischemic Attack: A Pilot Safety Study 2015 ·Current Therapeutic Research ·Matti Kivikko, Mikko Kuoppamäki, Lauri Soinne, Stig Sundberg, Pasi Pohjanjousi, Juha Ellmén, Risto O. Roine	12
5	Cost-benefits of incorporating levosimendan into cardiac surgery practice: German base case 2015 ·Journal of Medical Economics ·(unknown), Matti Kivikko, Matthias Heringlake, (unknown), (unknown), Marjo Apajasalo, Piero Pollesello	5
6	Cost Benefits Of Incorporating Levosimendan Into Cardiac Surgery Practice: German Base Case 2015 ·Value in Health ·(unknown), (unknown), (unknown), (unknown), Matti Kivikko, (unknown)	2
7	Intermittent levosimendan treatment in patients with severe congestive heart failure 2013 ·Clinical Research in Cardiology ·Petri Tuomainen, Jarkko Magga, (unknown), Kati Miettinen, (unknown), Esko Vanninen, Tomi Laitinen, Kirsi L. Timonen, Kari Punnonen, Ilkka Parviainen, Ari Uusaro, Olli Vuolteenaho, Matti Kivikko, Keijo Peuhkurinen	9
8	The clinical effects of levosimendan are not attenuated by sulfonylureas 2012 ·Scandinavian Cardiovascular Journal ·Matti Kivikko, Markku S. Nieminen, Piero Pollesello, Pasi Pohjanjousi, Wilson S. Colucci, John R. Teerlink, Alexandre Mebazaa	5
9	Beneficial association of β-blocker therapy on recovery from severe acute heart failure treatment: Data from the Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support trial* 2011 ·Critical Care Medicine ·Michael Böhm, Andreas Link, (unknown), Markku S. Nieminen, Gerasimos Filippatos, (unknown), Alain Cohen Solal, Bidan Huang, Robert J. Padley, Matti Kivikko, Alexandre Mebazaa	43
10	Oral levosimendan improves filling pressure and systolic function during long-term treatment 2011 ·Scandinavian Cardiovascular Journal ·(unknown), Matti Kivikko, Veli‐Pekka Harjola, Markku S. Nieminen, Mika Laine	12
11	Intravenous Levosimendan vs. Dobutamine in Acute Decompensated Heart Failure Patients on Beta-Blockers 2010 ·European Journal of Heart Failure ·Claes‐Håkan Bergh, Bert Andersson, Ulf Dahlström, Kolbjørn Forfang, Matti Kivikko, Toni Sarapohja, Bengt Ullman, Gerhard Wikström	57
12	Acetylation status does not affect levosimendan's hemodynamic effects in heart failure patients 2010 ·Scandinavian Cardiovascular Journal ·Matti Kivikko, Stig Sundberg, Mats O. Karlsson, Pasi Pohjanjousi, Wilson S. Colucci	6
13	Oral Levosimendan in Patients with Severe Chronic Heart Failure—The PERSIST Study 2008 ·European Journal of Heart Failure ·Markku S. Nieminen, John G.F. Cleland, Jaan Eha, Yuri Belenkov, Matti Kivikko, Pentti Põder, Toni Sarapohja	43
14	Pharmacokinetics of Intravenous Levosimendan and Its Metabolites in Subjects With Hepatic Impairment 2008 ·The Journal of Clinical Pharmacology ·(unknown), (unknown), (unknown), (unknown), Sari Häkkinen, Matti Kivikko, Pertti J. Pentikäinen	25
15	Repetitive Dosing of Intravenous Levosimendan Improves Pulmonary Hemodynamics in Patients With Pulmonary Hypertension: Results of a Pilot Study 2008 ·The Journal of Clinical Pharmacology ·Franz X. Kleber, Tom Bollmann, Mathias M. Borst, Angelika Costard‐Jäckle, Ralf Ewert, Matti Kivikko, (unknown), Pasi Pohjanjousi, (unknown), Gerhard Wikström	59
16	Duration of the Haemodynamic Action of a 24-h Infusion of Levosimendan in Patients with Congestive Heart Failure 2006 ·European Journal of Heart Failure ·Jyrki Lilleberg, Mikaela A. Laine, (unknown), Matti Kivikko, Pasi Pohjanjousi, Markku Kupari	99
17	Levosimendan: A New Inodilatory Drug for the Treatment of Decompensated Heart Failure 2005 ·Current Pharmaceutical Design ·Matti Kivikko, Lasse Lehtonen	35
18	Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendan 2004 ·British Journal of Clinical Pharmacology ·Saila Antila, Matti Kivikko, Lasse Lehtonen, Jaan Eha, (unknown), Pasi Pohjanjousi, Pertti J. Pentikäinen	55
19	Pharmacodynamics and Safety of a New Calcium Sensitizer, Levosimendan, and Its Metabolites during an Extended Infusion in Patients with Severe Heart Failure 2002 ·The Journal of Clinical Pharmacology ·Matti Kivikko, Saila Antila, Jaan Eha, Lasse Lehtonen, Pertti J. Pentikäinen	102
20	Effect of the Quality of Dietary Fat on the Hypertensive Effect of Salt and on Tissue Fatty Acid Composition in Spontaneously Hypertensive Rats 1986 ·Planta Medica ·(unknown), (unknown), R. Hiltunen, (unknown), Matti Kivikko, Heikki Karppanen	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact